Scientists have administered an artificial intelligence-designed virus to a patient with a serious bacterial infection, marking a potential breakthrough in the fight against bacteria that no longer respond to antibiotics.
A California-based startup, Radical Numerics, says a patient with a serious bacterial infection has received an experimental treatment containing viruses designed by its artificial intelligence model, Omnii-1.
The technology creates bacteriophages, or phages — viruses that infect and destroy bacteria without targeting human cells. Phage therapy is already being explored as an experimental treatment for severe bacterial infections, particularly in patients for whom conventional antibiotics have failed.
Rather than relying solely on finding a naturally occurring virus capable of attacking the bacteria, Omnii-1 is designed to modify viral components so they can better recognize and target the specific bacterial strain responsible for a patient’s infection.
How the AI-Designed Treatment Works
The company says its AI model could eventually reduce the time needed to develop a targeted phage treatment to just a few days.
Before administering the experimental therapy, researchers tested the AI-designed viruses against bacteria taken from the patient. According to Radical Numerics, the virus mixture successfully eliminated the patient’s antibiotic-resistant bacterial sample in laboratory tests.
The treatment was administered through a special access program that allows doctors to use experimental therapies when approved treatment options are limited.
Radical Numerics describes the case as the first reported use of AI-designed phages to treat a human patient. However, the announcement was published by the company and has not yet been confirmed in a peer-reviewed scientific study.
The company has not disclosed the patient’s diagnosis or provided information about whether the treatment improved the patient’s condition or cleared the infection.
Promising Research — and Biosafety Concerns
The development comes amid growing interest in using artificial intelligence to accelerate medical research, including the development of new approaches to fighting drug-resistant infections.
In August, researchers at Stanford University and the Arc Institute announced that they had used AI to design previously unseen viruses capable of killing E. coli bacteria in laboratory experiments.
Of nearly 300 AI-designed viral genomes synthesized and tested, 16 produced functional viruses. Those experiments were conducted in bacteria, not in human patients.
The research highlights the potential of AI to accelerate the development of targeted treatments, but it has also raised questions about biosafety.
Scientists have warned that AI systems capable of designing new viruses require strong safeguards, particularly as the technology advances and could potentially be adapted for purposes beyond treating bacterial infections.
For now, the Radical Numerics announcement represents an early step in applying AI-designed bacteriophages in human medicine. Whether the approach can safely and effectively treat patients remains to be established through clinical evidence.
